Nichi-Iko Records Double-digit Growth For 3Q
This article was originally published in PharmAsia News
Executive SummaryNichi-Iko reported generic drug sales grew by 16.8 percent to ¥46.9 billion for the third quarter ending Aug. 31. Net profit also increased by 2.7 percent to ¥2.7 billion
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.